Multi-Center Study for Adolescents with Melanoma, Rhabdomyosarcoma or Other Solid Tumors Undergoing Lymph Node Mapping
Nationwide Children’s Hospital is the first site in the United States participating in this multi-center research study designed to determine the detection and correlation rates of Lymphoseek and of a vital blue dye in lymph nodes and to assess these lymph nodes for the presence of tumor metastases in patients with melanoma and extremity rhabdomyosarcoma.
Why are we doing this study?
Melanoma and rhabdomyosarcoma are rare tumors in children and adolescents, but when present they can spread to lymph nodes, increasing the stage of the disease if this occurs. If these tumors have spread to the lymph nodes, the treatment is escalated to cover the regional spread of disease.
Who can participate in this study?
Researchers are looking for patients with melanoma, rhabdomyosarcoma, or other solid tumors between the ages of 12 to 18 years.
What will happen during this study?
This study is an Open-Label, Multicenter Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping.
All patients will receive treatment, and all study visits will occur at Nationwide Children’s Hospital. In addition, families will be compensated for time and travel.
If you are interested in participating in this study or would like additional information, please contact Lauren Bird, RN, clinical research nurse at Lauren.Bird@NationwideChildrens.org or 614-722-2699, or contact the primary investigator, Jennifer Aldrink, MD, at 614-722-0440.